GlassScriptPhysician profile
Kelsey Coffran
NPI 1265005532
$6,142.19
in general payments reported to CMS, 2019-2025
26 companies · $991 in 2025
The $991 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,605 · 2023: $2,703 · 2024: $842 · 2025: $991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,348 · Travel and Lodging: $1,009 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,347.65 |
| Travel and Lodging | $1,009.10 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $1,507.04 | 2022 | |
| Spinal Simplicity, LLC | $1,215.31 | 2023 | Ha Minuteman G3-R |
| Boston Scientific Corporation | $1,102.09 | 2022-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System, General - Therapies |
| Abbvie INC. | $446.16 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $312.74 | 2022-2024 | Belbuca, Xtampza |
| Galderma Laboratories, L.P. | $228.49 | 2025 | Nemluvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $226.41 | 2023-2024 | Relistor |
| Genzyme Corporation | $222.81 | 2025 | |
| Mml US, INC. | $159.19 | 2023 | Reactiv8 |
| Janssen Biotech, INC. | $128.02 | 2025 | Tremfya |
| Pfizer INC. | $124.00 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 | |
| Scilex Pharmaceuticals INC. | $60.32 | 2023-2024 | Ztlido |
| Amgen INC. | $51.73 | 2022-2025 | Otezla |
| Ucb, INC. | $35.54 | 2025 | Bimzelx |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $30.35 | 2023 | Stimrouter Implantable Kit, Durolane |
| Painteq LLC | $26.03 | 2023 | Painteq |
| Lilly USA, LLC | $25.49 | 2022-2023 | Emgality, Reyvow |
| Novo Nordisk INC | $24.38 | 2025 | Wegovy |
| Saluda Medical Americas, INC. | $23.91 | 2024 | Evoke |
| Medtronic, INC. | $21.14 | 2024 | Intellis Adaptivestim |
| Lnhc, INC | $20.48 | 2025 | Zelsuvmi |
| Regeneron Healthcare Solutions, INC. | $19.93 | 2025 | Dupixent |
| Organogenesis INC. | $19.06 | 2025 | Puraply Wound Matrix |
| Incyte Corporation | $16.51 | 2025 | Opzelura |
| Organon LLC | $15.07 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Coffran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.